This cluster reveals two parallel but mechanistically distinct therapeutic trends unified by a shared logic: targeting negative regulatory signaling pathways to halt tissue loss and dysfunction in metabolic and neurodegenerative disease. The first trend centers on dual blockade of ActRIIA/B ligands—GDF8 (myostatin) and Activin A—as a strategy to counteract muscle wasting. These two TGFβ-family ligands are established as the dominant negative regulators of muscle mass, signaling through the shared ActRIIA/B receptor to suppress muscle growth. Monoclonal antibodies against each target (anti-GDF8 and anti-ActA) have progressed through Phase 1 single- and multiple-dose trials in healthy postmenopausal females and males (NCT02943239), with preclinical validation in obese male mice and non-human primates, establishing both safety/tolerability and proof-of-mechanism for profound muscle growth upon receptor blockade.
The most compelling clinical application of this dual blockade strategy is as an adjunct to GLP-1 receptor agonist therapy for obesity. GLP-1 agonists drive weight loss through appetite suppression and caloric restriction, but this benefit is undermined by evolutionarily-conserved muscle loss mechanisms that respond to perceived food scarcity. By simultaneously blocking GDF8 and Activin A, dual blockade prevents this muscle loss while preserving—and even enhancing—fat loss, positioning this combination as a next-generation obesity therapeutic that improves body composition quality rather than simply reducing total weight. This same mechanism extends to muscle atrophy as an independent indication, reflecting a broader trend toward myostatin/activin pathway antagonism as a platform technology for muscle-preserving therapeutics across metabolic and degenerative conditions.
The second trend, embodied by DNL343, targets the integrated stress response (ISR) as a convergent node in neurodegeneration, particularly ALS. TDP-43 protein aggregation—the pathological hallmark observed in ALS patient spinal cord—triggers ISR activation, which is hypothesized to drive downstream neurodegeneration. DNL343, an eIF2B activator, inhibits this maladaptive ISR signaling, demonstrating efficacy in cellular ALS models and an inducible mouse model of TDP-43 pathology, where it transiently slowed locomotor deficit progression. Clinically, DNL343 has advanced from a Phase 1 healthy-participant trial (NCT04268784) to a Phase 1b ALS trial (NCT05006352), showing CNS penetration, once-daily dosing feasibility, and reduction of ISR biomarkers in both CSF and peripheral blood mononuclear cells—biomarker evidence bridging preclinical mechanism to human target engagement.
Together, these programs illustrate a broader macro trend in translational neuromuscular and metabolic research: precise pathway-level interception (ActRIIA/B ligand blockade; eIF2B-mediated ISR inhibition) to reverse or prevent tissue-level loss of function, validated through rigorous biomarker-driven early-phase trials that emphasize safety, target engagement, and mechanistic proof before efficacy expansion.